Last reviewed · How we verify
SYN818 and Olaparib will be administered
At a glance
| Generic name | SYN818 and Olaparib will be administered |
|---|---|
| Sponsor | Hangzhou SynRx Therapeutics Biomedical Technology Co., Ltd |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of SYN818 With Olaparib for the Treatment of Locally Advanced or Metastatic Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: